UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
September 15, 1998
---------------------------------
(Date of earliest event reported)
Cephalon, Inc.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19119 23-2484489
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) ID No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(215) 344-0200
--------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
---------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
ITEM 5. OTHER EVENTS.
On September 15, 1998, Cephalon, Inc. (the "Registrant") announced that
Cephalon-Chiron B.V. has withdrawn its application to the European Medicines
Evaluation Agency (EMEA) seeking clearance to market MYOTROPHIN(R) (mecasermin)
Injection in Europe for the treatment of amyotrophic lateral sclerosis (ALS or
motor neuron disease).
On September 18, 1998, the Registrant announced the first findings from
preclinical studies of its compound, CEP-701, for the treatment of pancreatic
ductal adenocarcinoma (PDAC). The results presented on September 18, 1998 at
the Baltic Pancreas Meeting in Germany demonstrate that CEP-701 can
significantly decrease tumor growth as well as inhibit tumor cell invasion in
PDAC animal models.
The Registrant hereby attaches both releases as Exhibits 99.1 and 99.2,
respectively, which are thereby made a part of this Item 5.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Business Acquired: None
------------------------------------------
(b) Pro Forma Financial Information: None
--------------------------------
(c) Exhibits: Reference is made to the Exhibit Index annexed hereto and
--------
made a part hereof.
SIGNATURES
-----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CEPHALON, INC.
Date: September 23, 1998 By: /s/ Bruce A. Peacock
------------------ ---------------------------------------
Bruce A. Peacock
Executive Vice President and
Chief Operating Officer
EXHIBIT INDEX
-------------
EXHIBIT PAGE
- ------- ----
99.1 Press Release dated September 15, 1998
99.2 Press Release dated September 18, 1998